FDA
-
-
-
-
-
-
-
PMV Pharmaceuticals to present rezatapopt data at cancer conference
-
-
-
-
-
-
-
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
-
-
-
-
-
-
-
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
-
-
-
-
-
-
-
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
PMV Pharmaceuticals (PMVP) Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA in Patients with Advanced Solid Tumors
-
-
-
-
-
-
-
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

